Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07599176 · ClinicalTrials.gov registry record · Phase 1
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
A Phase 1 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT07599176: Recruiting Phase 1 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT07599176 is a Phase 1 study that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 90 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07599176, a Phase 1 study, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens. The goal is to aim for higher percentage of donor cells to stably remain in the recipients long term.
Primary Outcome
percentage of donor myeloid chimerism
Interventions
- DRUG Alemtuzumab
- DRUG Abatacept
- RADIATION Total Body Irradiation
- OTHER Research blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2035-06-30 |
| Phase | Phase 1 |
What NCT07599176 shows while recruiting
NCT07599176 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 4 interventions - of which Alemtuzumab is the first listed.
NCT07599176 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07599176 about?
NCT07599176 is a clinical study titled "Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors". This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens. The goal is to aim for higher percentage of donor cells...
What is the current status of trial NCT07599176?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2026-07-15. Estimated completion is 2035-06-30.
What interventions are being tested in trial NCT07599176?
The interventions under investigation include: Alemtuzumab (DRUG), Abatacept (DRUG), Total Body Irradiation (RADIATION), Research blood draw (OTHER).
Who is sponsoring clinical trial NCT07599176?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07599176's enrollment target sits among peer trials
90 628th of 2000 higher than 1,352 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI